Trillium Therapeutics (Trillium Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Change In Inventory?

Trillium Therapeutics's change in inventory for the quarter that ended in Sep. 2021 was $0.00 Mil. It means Trillium Therapeutics's inventory stayed the same from Jun. 2021 to Sep. 2021 .

Trillium Therapeutics's change in inventory for the fiscal year that ended in Dec. 2020 was $0.00 Mil. It means Trillium Therapeutics's inventory stayed the same from Dec. 2019 to Dec. 2020 .

Trillium Therapeutics's Total Inventories for the quarter that ended in Sep. 2021 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Trillium Therapeutics Change In Inventory Historical Data

The historical data trend for Trillium Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Change In Inventory Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Inventory

Get a 7-Day Free Trial

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Trillium Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Trillium Therapeutics (NAS:TRIL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Trillium Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Trillium Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Trillium Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Trillium Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.